Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations

The purpose of this study was to evaluate the mechanisms of aggregate formation and excipient stabilization in freeze-dried formulations of a recombinant humanized monoclonal antibody. Protein degradation was measured using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) and native size exclusion chromatography, and protein structure was studied using Fourier transform-infrared spectrometry and circular dichroism. The results showed that protein aggregates present following reconstitution were composed of native antibody structure and a reduced amount of free thiol when compared to protein monomer, which implied that intermolecular disulfides were involved in the aggregation mechanism. An excipient-free formulation resulted in reversible solid-state protein structural alteration and increased aggregation during storage. This correlated with dehydration to an extent that the amount of water was less than the estimated number of surface-accessible hydrogen-bonding sites on the protein. Improved native-like solid-state protein structure and reduced aggregation were obtained by formulation with enough carbohydrate to fulfill the hydrogen-bonding sites on the surface of the protein. Carbohydrate in excess of this concentration has less of an influence on protein aggregation. Reduced aggregation during storage was obtained by the addition of sufficient excipient to both stabilized solid-state protein structure and provide an environment that consisted of an amorphous glassy state matrix.

[1]  W. Caughey,et al.  Protein secondary structures in water from second-derivative amide I infrared spectra. , 1990, Biochemistry.

[2]  W. Krueger,et al.  An infrared and circular dichroism combined approach to the analysis of protein secondary structure. , 1991, Analytical biochemistry.

[3]  Steven J. Shire,et al.  The Effect of Formulation Excipients on Protein Stability and Aerosol Performance of Spray-Dried Powders of a Recombinant Humanized Anti-IgE Monoclonal Antibody1 , 1999, Pharmaceutical Research.

[4]  C. Hsu,et al.  Determining the water sorption monolayer of lyophilized pharmaceutical proteins. , 1997, Journal of pharmaceutical sciences.

[5]  J L Cleland,et al.  A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. , 2001, Journal of pharmaceutical sciences.

[6]  H. Mantsch,et al.  New insight into protein secondary structure from resolution-enhanced infrared spectra. , 1988, Biochimica et biophysica acta.

[7]  Michael J. Pikal,et al.  Freeze‐Drying of Proteins. Process, Formulation, and Stability. , 1995 .

[8]  R L Blakeley,et al.  Ellman's reagent: 5,5'-dithiobis(2-nitrobenzoic acid)--a reexamination. , 1979, Analytical biochemistry.

[9]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[10]  Tracy Chen,et al.  Formulation concerns of protein drugs , 1992 .

[11]  S. Allison,et al.  Infrared spectroscopic studies of lyophilization- and temperature-induced protein aggregation. , 1995, Journal of pharmaceutical sciences.

[12]  Chung C. Hsu,et al.  The effect of sugars and buffer excipients on the stabilization of a lyophilized formulation for an anti-IgE humanized monoclonal antibody , 1996 .

[13]  S. Shire.  Challenges and Issues in the Development of Formulations of Protein Pharmaceuticals , 1999 .

[14]  Chung C. Hsu,et al.  Determining the optimum residual moisture in lyophilized protein pharmaceuticals. , 1992, Developments in biological standardization.

[15]  R. Borchardt,et al.  Stability of Protein Pharmaceuticals , 1989, Pharmaceutical Research.

[16]  E. Padlan.  On the nature of antibody combining sites: Unusual structural features that may confer on these sites an enhanced capacity for binding ligands , 1990, Proteins.

[17]  K. A. Connors.  The Karl Fischer Titration of Water , 1988 .

[18]  J. Carpenter,et al.  An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. , 1989, Biochemistry.

[19]  T. Arakawa,et al.  Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. , 1993, Biophysical journal.

[20]  L. Presta,et al.  Humanization of an anti-p 185 HER 2 antibody for human cancer therapy ( antibody engineering / site-directed mutagenesis / c-erbB2 / neu ) , 2022 .

[21]  Chung C. Hsu,et al.  Feasibility Study on Spray-Drying Protein Pharmaceuticals: Recombinant Human Growth Hormone and Tissue-Type Plasminogen Activator , 2004, Pharmaceutical Research.

[22]  Chung C. Hsu,et al.  Fourier‐transform Infrared Spectroscopic Analysis of the Secondary Structure of Recombinant Humanized Immunoglobulin G , 1997 .

[23]  Michael J. Hageman,et al.  THE ROLE OF MOISTURE IN PROTEIN STABILITY , 1988 .

[24]  Michael J. Pikal,et al.  Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice , 1997, Pharmaceutical Research.

[25]  A. Klibanov,et al.  Solid-phase aggregation of proteins under pharmaceutically relevant conditions. , 1994, Journal of pharmaceutical sciences.

[26]  K. Dill.  Dominant forces in protein folding. , 1990, Biochemistry.

[27]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Presta,et al.  Humanization of an antibody directed against IgE. , 1993, Journal of immunology.

[29]  Fen-Ni Fu,et al.  Secondary Structure Estimation of Proteins Using the Amide III Region of Fourier Transform Infrared Spectroscopy: Application to Analyze Calcium-Binding-Induced Structural Changes in Calsequestrin , 1994 .

[30]  Chung C. Hsu,et al.  Effect of Moisture on the Stability of a Lyophilized Humanized Monoclonal Antibody Formulation , 2001, Pharmaceutical Research.